Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 19/20 | 0.66 |
| ▸ | PRKCA | P17252 | 3/20 | 0.64 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.64 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | PRKCB | P05771 | 1/20 | 0.48 |
| ▸ | PRKCH | P24723 | 1/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424642 | 0.94 | PRKD1 (0.73) | PRKD1PRKCAPRKCDPRKD2ADRB1 | |
| SCHEMBL1424479 | 0.93 | PRKD1 (0.63) | PRKD1PRKCAPRKCDPRKD2ADRB1 | |
| SCHEMBL1423973 | 0.92 | PRKD1 (0.62) | PRKD1PRKCAPRKCDPRKD2ADRB1 | |
| SCHEMBL1424225 | 0.89 | PRKD1 (0.68) | PRKD1PRKCAPRKCDPRKD2ADRB1 | |
| SCHEMBL1423988 | 0.89 | PRKD1 (0.71) | PRKD1PRKCAPRKCDPRKD2ADRB1 | |
| SCHEMBL8134984 | 0.89 | PRKD1 (0.67) | PRKD1PRKCAPRKCDPRKD2ADRB1 | |
| SCHEMBL1424191 | 0.87 | PRKD1 (0.58) | PRKD1PRKCAPRKCDPRKD2ADRB1 | |
| SCHEMBL1424482 | 0.86 | PRKD1 (0.74) | PRKD1PRKCAPRKCDPRKD2ADRB1 | |
| SCHEMBL1423961 | 0.86 | PRKD1 (0.63) | PRKD1PRKCAPRKCDPRKD2ADRB1 | |
| SCHEMBL1423948 | 0.85 | PRKD1 (0.73) | PRKD1PRKCAPRKCDPRKD2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142685-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142685-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142685-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| EP-2144909-B1 | [2,6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| EP-2144909-A1 | [2, 6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | Novartis Ag (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008122615-A1 | [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122615-A1 | [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142685-A1 | ORGANIC COMPOUNDS | MARK1, PKN1, MARK2 | PRKD1 164/4885PRKCA 38/4885PRKCD 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.